A new in situ remediation concept termed a Horizontal Reactive Media Treatment Well (HRX Well®) is presented that utilizes a horizontal well filled with reactive media to passively treat contaminated groundwater in situ. The approach involves the use of a large‐diameter directionally drilled horizontal well filled with solid reactive media installed parallel to the direction of groundwater flow. The engineered contrast in hydraulic conductivity between the high in‐well reactive media and the ambient aquifer hydraulic conductivity results in the passive capture, treatment, and discharge back to the aquifer of proportionally large volumes of groundwater. Capture and treatment widths of up to tens of feet can be achieved for many aquifer settings, and reductions in downgradient concentrations and contaminant mass flux are nearly immediate. Many different types of solid‐phase reactive treatment media are already available (zero valent iron, granular activated carbon, biodegradable particulate organic matter, slow‐release oxidants, ion exchange resins, zeolite, apatite, etc.). Therefore, this concept could be used to address a wide range of contaminants. Laboratory and pilot‐scale test results and numerical flow and transport model simulations are presented that validate the concept. The HRX Well can access contaminants not accessible by conventional vertical drilling and requires no aboveground treatment or footprint and requires limited ongoing maintenance. A focused feasibility evaluation and alternatives analysis highlights the potential cost and sustainability advantages of the HRX Well compared to groundwater extraction and treatment systems or funnel and gate permeable reactive barrier technologies for long‐term plume treatment. This paper also presents considerations for design and implementation for a planned upcoming field installation.

While investigating the antistreptolysin content of patients' sera according to Todd's method (1-3), we found that the hemolytic titer of one given streptolysin might vary considerably within a short period. The purposes of this communication are: first, to show that although the hemolytic titer of such a streptolysin does vary, its power of combining with antistreptolysin is constant under certain conditions; and second, to discuss the effect of this phenomenon upon the standardization of streptolysins which are to be used in testing sera for antistreptolysins.Neill and Mallory (4) demonstrated that streptolysin may exist in at least two forms: (a) reduced and hemolytic, and (b) oxidized and non-hemolytic. They further showed that these two forms are easily reversible, one to the other, by oxidation and reduction. Such a reversibility would readily explain variations in hemolytic titer because the degree of hemolysis depends upon the amount of the reduced (hemolytic) form alone; such a reversibility, nevertheless, might not change the total streptolysin present in a given lot of hemolytic broth. It seemed to us that this hypothesis predicates a constant combining capacity of streptolysin with antistreptolysin even though the hemolytic strength might vary. In order to test it the following experiments were performed.Large amounts of streptolysins Nos. 32, 33, and 35 were made. Each batch was divided into several different samples and each sample was subjected to different conditions, in order to obtain different hemolytic titers. In these experiments, the amount of hemolytic broth required to hemolyze completely 0.5 cc. of 5 per cent red blood ceils in 1 hour was determined; this is known as 1 ~r.H.D. (minimal 277 on

IN H. STREPTOCOCCAL INFECTIONS 849 over a 4-day period into subcutaneous areas remote from the cropsacs. Here again we find another striking example of the importance of route of injection. It is notable also that if subcutaneous instead of intramuscular injection were used in the "threshold" bioassay method of McShan and Turner3 a unit of notably smaller size than that described by them would be expected, unless indeed seepage into the subcutaneous area normally occurs after their injections into very superficial parts of the pectoral muscles of the pigeon.In our tests with the effect of route of administration on the potency of pituitary F.S.H. we have failed to obtain a significant difference (weights of testes of immature pigeons). And, again unlike prolactin, division of the daily dose of F.S.H. into 3 timespaced injections failed to change the amount of the response of the testes.In the rat, however, Collip has found subcutaneoiis injection of gonadotropic hormone much more effective than intraperitoneal injection.In young pigeons of the same age and race the response of the crop-glands to prolactin administered by 5 different routes has been studied and found to differ widely. Subcutaneous and intracutaneous injections are about 11 times as efficient as intravenous injections, about 5 times as efficient as intramuscular injections, and about 8 times as efficient as intraperitoneal injections at the dosage level used.Sumwry.

No abstract

No abstract